Author Archives: wesley

Hunan MPA Grants First Authorization to Xiangjiang New Area Evaluation Center – 15 Devolved Review and Inspection Items Accelerate Local Drug, Device and Cosmetics Oversight in Changsha

Changsha, China – 15 Sep 2026 – The Hunan Provincial Medical Products Administration (Hunan MPA) announced that, effective 15 September 2026, it is granting its first authorization to the Hunan Xiangjiang New Area Drug Evaluation and Verification Center (Hunan Provincial MPA Evaluation and Verification Xiangjiang New Area Branch Center) to handle 6 review items, 7 verification items and 2 supervisory inspection items covering drugs, medical devices and cosmetics within the Xiangjiang New Area, with the scope of devolved authority to be dynamically adjusted based on the branch center’s capability.

Authorization Snapshot

ItemDetail
AuthorityHunan Provincial Medical Products Administration (Hunan MPA), China
ActionFirst delegation of review, verification and inspection authority to a New Area branch center
RecipientHunan Xiangjiang New Area Drug Evaluation and Verification Center (Hunan MPA Evaluation and Verification Xiangjiang New Area Branch Center)
Effective Date15 September 2026
Delegated Scope6 review items, 7 verification items, 2 supervisory inspection items – covering drugs, medical devices and cosmetics within the Xiangjiang New Area
Policy BasisState Council General Office Document 〔2024〕 No. 53 – Opinions on Comprehensively Deepening Drug and Medical Device Regulatory Reform to Promote High‑Quality Development of the Pharmaceutical Industry
Adjustment MechanismDynamic adjustment of delegated items based on the branch center’s review and verification capability
Original Announcementmpa.hunan.gov.cn (published 16 September 2026)

Authorization Details & Governance

  • Full Itemized List: The annex — Catalogue of First‑Batch Authorized Items of the Xiangjiang New Area Branch Center — enumerates each delegated matter across review (6), verification (7) and supervisory inspection (2); individual item specifications were not disclosed in the announcement text itself.
  • Three‑Product Coverage: The devolved authority spans drugs, medical devices and cosmetics, giving companies in the New Area a single local channel for these regulatory interactions.
  • Capability‑Linked Devolution: The Hunan MPA will dynamically adjust the authorized scope in line with the branch center’s demonstrated review and verification capacity — a built‑in performance gate rather than a one‑off transfer.
  • Reform Context: The move implements Document 〔2024〕 No. 53, which directs deeper review‑and‑approval system reform and higher regulatory efficiency as levers for high‑quality pharmaceutical industry development.

Sector Background

  • Decentralization Trend: Provincial MPAs have progressively devolved technical review and on‑site inspection functions to regional centers, mirroring the national NMPA reform agenda of shortening approval pathways while retaining oversight.
  • Xiangjiang New Area: Established in 2015 as a national‑level new area, the zone hosts Changsha’s biomedical and life‑sciences cluster, with dedicated industrial parks attracting drug, device and cosmetics manufacturers seeking proximity to regulators.
  • Branch‑Center Model: Setting up an evaluation and verification branch inside an industrial park places regulatory capacity next to industry — a model previously piloted in other Chinese provinces’ development zones.

Market Impact & Outlook

  • Faster Local Processing: Companies headquartered or operating in the Xiangjiang New Area can expect shorter turnaround for the delegated review, verification and inspection matters without routing through the provincial capital’s central queue.
  • Investment Signal: On‑site regulatory capacity is a tangible incentive for life‑sciences investment decisions, strengthening the New Area’s bid to attract drug, device and cosmetics projects.
  • Scalable Precedent: The dynamic adjustment clause signals that the delegated catalogue may expand as the branch matures — worth monitoring for sponsors planning Hunan registrations or site relocations.
  • Compliance Posture: Manufacturers in the zone should map their pending and planned regulatory interactions against the 15 authorized items to determine which now run through the branch center versus the provincial MPA.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the scope, timing and evolution of regulatory authority delegated to the Xiangjiang New Area Branch Center. The authorized item list remains subject to dynamic adjustment by the Hunan MPA, and actual review timelines, scope changes and regulatory outcomes may differ materially from current expectations.-China Health Reform Pulse

Policy Source: http://mpa.hunan.gov.cn/mpa/xxgk/tzgg/wjtz/202609/t20260916_34065635.html

China’s NHSA Launches Work Plan for First National Medical Insurance Medical Service Catalogue – 13 Clinical Categories in Batch One Reshape Reimbursement Rules for Providers Nationwide

Beijing, China – 16 Sep 2026 – China’s National Healthcare Security Administration (NHSA) released the Work Plan for Formulating the First Batch of the National Basic Medical Insurance Medical Service Item Catalogue, establishing a unified national catalogue of reimbursable medical service items — starting with 13 clinical categories including cardiovascular, respiratory, ophthalmology, gynecology, radiotherapy, anesthesia, nursing, clinical scale assessment, dental implants, assisted reproduction, obstetrics, radiological examination, and rehabilitation — to be applied first to cross‑province direct settlement and then progressively aligned with provincial payment scopes.

Policy Snapshot

ItemDetail
AuthorityNational Healthcare Security Administration (NHSA), China
DocumentWork Plan for Formulating the First Batch of the National Basic Medical Insurance Medical Service Item Catalogue
Release Date16 September 2026
Legal BasisHealthcare Security Law of the PRC; CPC Central Committee & State Council Opinions on Deepening Healthcare Security System Reform; 1999 MOHRSS rules on diagnostic/treatment item management
First Batch Scope13 categories (incl. related items in other categories), to be expanded in batches alongside the national medical service price project listing guidelines
Initial ApplicationCross‑province direct settlement for out‑of‑town treatment; subsequently linked with provincial insurance payment scopes

Inclusion & Exclusion Criteria

  • Inclusion Baseline: Items must be listed in the current national medical service price project listing guidelines (trial), be clinically necessary, safe, effective and appropriately priced, and pose controllable impact on basic medical insurance fund expenditure without threatening fund security.
  • Explicit Exclusions: Items subject to market‑regulated pricing; non‑disease‑treatment services such as cosmetic procedures, weight loss, health checkups, prevention and wellness; services with insufficient clinical application, uncertain efficacy, or major safety risks; and anything else outside the basic insurance coverage scope.
  • Guiding Principle: The catalogue adheres to the “basic coverage” positioning of basic medical insurance — acting within capability, keeping total volume stable, and ensuring smooth transition, weighing fund affordability, clinical demand and social impact.

Work Program – Three Phases

  • Preparation Phase: Establish a dedicated task force and expert database; finalize work rules covering integrity, confidentiality and conflict‑of‑interest recusal; collect provincial data on price‑listing implementation, service pricing and payment status; and run fund modeling on the first batch’s insurance expenditure and the overall national cost envelope for medical services.
  • Review Phase: A survey across representative medical institutions at all levels in 31 provinces (regions, municipalities) plus the Xinjiang Production and Construction Corps; joint review by management and clinical experts scoring each item on inclusion merit, health benefit, clinical need, equity and cost‑effectiveness; expert discussion of restricted payment scopes; and a fund impact assessment with local insurance authorities before shortlisting items.
  • Publication Phase: The first‑batch catalogue is finalized based on expert opinions and fund impact modeling, submitted for approval per procedure, then issued to guide local implementation.

Governance & Expert Oversight

  • Expert Composition: Reviewers — insurance management, price management, health economics/HTA and clinical experts — are recommended by relevant departments or randomly drawn from the expert pool, with geographic balance, representation across institution types and tiers, and inclusion of primary‑care institution representatives.
  • Clinical Reviewer Scope: Clinical experts evaluate items only within their specialty fields.
  • Supervision Mechanisms: Disciplinary inspection and supervision bodies are invited to oversee preparation, review and publication; internal controls mandate role accountability, confidentiality, recusal and liability rules; experts sign non‑disclosure agreements, must commit to impartial service, are barred from unauthorized public activity in the catalogue‑expert capacity, and all proceedings are fully documented to preserve independence.

Market Impact & Outlook

  • Reimbursement Architecture: A unified national service catalogue replaces the current patchwork of provincial coverage lists — a structural shift for hospitals’ revenue predictability and for cross‑province settlement efficiency serving China’s large migrant population.
  • Provider Strategy: Medical institutions should map their service portfolios against the 13 first‑batch categories and the inclusion criteria, anticipating which items may face restricted payment scopes or exclusion as market‑priced services.
  • Sector Winners & Watchpoints: Categories inside the catalogue — notably dental implants, assisted reproduction, rehabilitation and radiotherapy — gain clearer reimbursement visibility, while cosmetic, wellness and weight‑loss services are explicitly ring‑fenced outside basic insurance.
  • Phased Expansion: Subsequent batches will follow the rollout of national price project listing guidelines, signaling a multi‑year build‑out toward full national standardization of insured medical services.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the formulation, approval and implementation of China’s national medical insurance medical service item catalogue. The work plan remains subject to consultation, expert review and fund impact assessment; the final catalogue composition, payment restrictions, effective dates and local implementation may differ materially from current expectations.-China Health Reform Pulse

Policy Source: https://ylbz.gansu.gov.cn/ylbzj/c105248/202609/174394881.shtml

NMPA’s CMDE Opens Public Consultation on Revised Guidelines for Tuberculosis Drug‑Resistance Gene Mutation Detection Reagents – 2026 Revision Signals Tightened Review Standards for Molecular TB Diagnostics in China

Beijing, China – 16 Sep 2026 – The Center for Medical Device Evaluation (CMDE) of China’s National Medical Products Administration (NMPA) announced a public consultation on the revised draft guideline, Guidelines for Registration and Review of Mycobacterium tuberculosis Complex Resistance Gene Mutation Detection Reagents (2026 Revised Edition) (Draft for Comments), aimed at standardizing technical review requirements and guiding registration applicants in preparing submission dossiers, with feedback due by 15 October 2026.

Consultation Snapshot

ItemDetail
AgencyCMDE, under the National Medical Products Administration (NMPA), China
ActionPublic solicitation of opinions on a revised draft registration review guideline
DocumentGuidelines for Registration and Review of Mycobacterium tuberculosis Complex Resistance Gene Mutation Detection Reagents (2026 Revised Edition, Draft for Comments)
PurposeStandardize technical review requirements; guide applicants in preparing and writing registration dossiers
Notice Date16 September 2026
Comment Deadline15 October 2026, via email using the prescribed feedback form and subject‑line naming convention
Original Noticecmde.org.cn (published 16 September 2026)

Guideline Scope & Submission Channels

  • Product Scope: The guideline covers in vitro diagnostic reagents that detect resistance‑associated gene mutations in the Mycobacterium tuberculosis complex — molecular tests used to identify drug‑resistant TB (including multidrug‑resistant TB) directly from clinical specimens, in contrast to slower culture‑based drug susceptibility testing.
  • Revision, Not First Edition: CMDE has revised the existing guideline rather than issuing an inaugural document, indicating updates to review expectations accumulated from prior registration experience. The specific changes were not disclosed in the notice; the full draft is available for download from CMDE.
  • Submission Format: Comments must be filed via the official feedback form (Annex 2) by email, with subject lines and file names formatted as “Guideline name – feedback + organization name.”
  • Contacts: Cheng Xi, Liu Rongzhi (+86‑10‑86452580, +86‑10‑86452532; chengxi@cmde.org.cn, liurz@cmde.org.cn).

Sector Background

  • Molecular Resistance Detection: Gene mutation assays — typically PCR‑based — identify resistance‑conferring mutations (e.g., in rpoB for rifampicin resistance) within hours, enabling rapid treatment decisions versus weeks for phenotypic testing.
  • Public Health Priority: China remains among the countries with the highest TB and multidrug‑resistant TB burden globally, making fast, accurate resistance detection central to national TB control programs and the WHO End TB Strategy.
  • IVD Registration Environment: CMDE technical review guidelines define the evidentiary expectations (analytical performance, clinical studies, reference comparators) for IVD registration in China; public consultation is the standard step before finalization.

Market Impact & Outlook

  • Regulatory Predictability: A revised, codified standard reduces dossier ambiguity for IVD sponsors and shortens the review cycle for resistance‑detection assays targeting the M. tuberculosis complex.
  • Competitive Landscape: Domestic molecular diagnostics developers — alongside global IVD players active in China’s TB testing market — should benchmark their clinical evidence and performance claims against the 2026 draft before launching new registrations or renewals.
  • Portfolio Implications: Manufacturers with existing TB resistance‑detection products should assess whether current dossiers and performance data meet the revised expectations, particularly on mutation coverage and clinical concordance requirements.
  • Participation Window: Stakeholders have until 15 October 2026 to influence the final guideline — an opportunity to raise practical issues on reference standards, comparator selection, and multi‑center clinical study design.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory timelines, the finalization of the draft guideline, and its potential impact on in vitro diagnostic registration in China. The draft is subject to revision based on public feedback, and actual requirements, effective dates, and review outcomes may differ materially.-China Health Reform Pulse

Policy Source: https://www.cmde.org.cn/xwdt/zxyw/20260916144510144.html